PharmiWeb.com - Global Pharma News & Resources
13-Dec-2022

Glenmark’s antimalarial wins Highly Commended at Pharmacy MVP Awards

Watford, England, December 13, 2022: Glenmark has received Highly Commended in the Pharmacy MVP Awards for its OTC antimalarial, Maloff Protect.

Maloff Protect is indicated for the chemoprophylaxis of plasmodium falciparum (P. Falciparum) malaria in adults and contains two active ingredients: atovaquone and proguanil hydrochloride.

The film-coated tablets should be taken daily from one to two days before travel to a malaria-affected area and for a further seven days after leaving the area. The 250mg/100mg tablets are available through pharmacy, without a prescription, over-the-counter or online for adults.

Being able to sell Maloff Protect directly to customers presents pharmacies with the opportunity to provide an extended service for adults aged 18 and over. Selling a 24 pack at RRP excluding VAT offers a profit margin of £8.56, and a 36 pack offers a profit margin of £11.45. Customers purchasing travel-related items such as bug spray, compression socks or miniature toiletries might be eligible for Maloff Protect. Keep an eye out for purchases of this nature and don’t miss an opportunity to support your customers further.

When infected mosquitoes bite, they can pass the malaria parasite, Plasmodium falciparum, into the bloodstream. Maloff Protect works by killing the parasite.

UK General Manager at Glenmark, Martin Imms, said: “We are delighted to have been awarded Highly Commended for Maloff Protect. As always, our confidence in our innovative products is backed up by their performance in clinical trials and efficacy in patients across the world. Once again, our innovation and passion in delivering accessible medicines for patients to treat or protect against common illnesses and diseases, has been recognised by the pharmaceutical profession.

“Malaria is a serious illness and can be fatal in some cases. We are proud of the recognition we have received from the Pharmacy Community over the years, while enabling people to get malaria protection direct from a pharmacy, making their travel preparations simpler.”

Glenmark is a global research-led pharmaceutical company with presence across generics, specialty and OTC businesses and with operations in over 50 countries.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Glenmark Pharmaceuticals Europe Ltd medical_information@glenmarkpharma.com or call 0800 458 0383

 

 

Name of product: Maloff Protect 250mg/100mg tablets.

List of actives: atovaquone, proguanil

PL number: PL 25258/0166.

Name and address of PL holder: Glenmark Pharmaceuticals Europe Limited, Laxmi House, 2 B Draycott Avenue, Kenton, Middlesex, HA3 0BU.

Supply classification (P/GSL) P. Indication(s) Chemoprophylaxis of Plasmodium falciparum (P. Falciparum) malaria in adults. Check official guidelines (e.g. World Health Organisation (WHO) and public health authorities’ guidelines) before dispensing. Contraindications: hypersensitivity to atovaquone, proguanil or excipients, renal disease, hepatic impairment, children and adolescents. Precautions: if vomiting occurs within one hour of dosing repeat dose. If allergic reaction develops, discontinue use promptly and seek medical treatment. Refer the following patients to a doctor or other qualified prescriber: those taking etoposide, rifampicin, rifabutin, metoclopramide, warfarin and other anticoagulants, tetracycline, indinavir, efavirenz, zidovudine, boosted protease inhibitors, those with a history of depression or seizures, those with TB, patients who are pregnant, planning to become pregnant or those breast feeding. Safety and effectiveness has not been established in patients <40kg. Remind travellers of the need for a full travel consultation. The most common side effects are headache, abdominal pain and diarrhoea. Other important reactions reported are severe allergic reactions, pancytopenia in patients with severe renal impairment, severe skin reactions, seizure, hallucinations, liver inflammation, depression. Dosage and method used: One tablet daily with food or a milky drink at the same time each day. Commence 1-2 days prior to entering malaria-endemic area, continue for the duration of the stay plus seven days after leaving the area. The maximum duration of travel for which Maloff Protect can be supplied without prescription is 12 weeks (93 tablets). For longer durations of travel, advice should be sought from a doctor or other qualified prescriber.  RRP (excluding VAT): 24 Tablet Pack = £39.00, 36 Tablet Pack = £58.50. Date of EI Creation April 2022.

Editor Details

Related Links

Last Updated: 13-Dec-2022